Bolt Biotherapeutics, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Bolt is a clinical-stage immuno-oncology company developing antibody-based therapies; it had no product-sale revenue. Financial amounts below are in millions of dollars unless noted.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Collaboration revenue | $1.4 | $0 | $2.2 | $0 |
| Research and development expense | $18.9 | $19.7 | $37.3 | $33.8 |
| General and administrative expense | $5.5 | $4.1 | $11.8 | $8.4 |
| Operating loss | $(23.1) | $(23.8) | $(46.9) | $(42.2) |
| Net loss | $(22.7) | $(23.6) | $(46.3) | $(48.0) |
| Net loss per share | $(0.61) | $(0.64) | $(1.25) | $(1.65) |
| Net cash used in operations | — | $(45.1) | $(20.5) |
- At June 30, cash and cash equivalents were $22.6 million and available-for-sale investments were $201.0 million, for a combined $223.6 million. This compares with $271.6 million at December 31, 2021.
- Total assets were $260.2 million; total liabilities were $52.3 million. The filing reports no outstanding debt. Operating lease liabilities totaled $22.9 million, including $2.1 million current and $20.7 million non-current.
- Accumulated deficit was $253.3 million. No operating or net profit margins are meaningful for this loss-making, pre-commercial company.
Changes versus prior comparable periods
- Q2 operating loss narrowed by $0.7 million year over year, while net loss narrowed by $0.9 million. Collaboration revenue began contributing in 2022, principally from Genmab and Innovent.
- For the first half, operating loss widened by $4.7 million as R&D and G&A expenses rose. Net loss was lower by $1.7 million, partly because the 2021 comparison included a $6.1 million expense from remeasuring a preferred-stock purchase-right liability.
- First-half operating cash use increased to $45.1 million from $20.5 million. Management cited net losses and changes in operating assets and liabilities; 2021 cash flow benefited from deferred revenue and other working-capital movements.
- Investments declined from $244.2 million at year-end to $201.0 million at June 30. The company reported a $1.8 million accumulated unrealized loss on investments, compared with $0.3 million at year-end.
Outlook, management commentary, and risks
- Management said June 30 cash, cash equivalents, and investments were expected to fund operations for at least 12 months after the report’s August 10, 2022 issuance. It expects continuing losses and says longer-term funding may require equity or debt financing, collaborations, licenses, or other capital sources.
- In July 2022, after the reporting period, Bolt completed a portfolio review: it planned to advance BDC-1001 and BDC-3042, wind down BDC-2034 development, and pause other early-stage research programs.
- BDC-1001 was in a Phase 1/2 trial, including a combination study with Bristol Myers Squibb’s nivolumab. The company’s collaborations with Toray, Genmab, and Innovent provide research-related payments; potential milestone and royalty proceeds are uncertain and excluded from current transaction prices.
- Revenue depends on the timing and progress of collaborations; the Toray research plan was being reevaluated. The Innovent stock-purchase options expired unexercised in May 2022.
- Key risks include clinical and regulatory uncertainty, need for additional capital, reliance on single-source suppliers and manufacturers, and possible disruption from COVID-19. Management said the pandemic had not materially harmed productivity or business to date, but future effects remained uncertain.
- The company had a material weakness in internal control over financial reporting, related to insufficient accounting staffing, expertise, formal policies, and controls. Remediation steps were underway, but the weakness was not yet considered remediated. No material changes to previously disclosed risk factors were reported.
- A $250 million shelf registration and a $75 million at-the-market program were available; no ATM shares had been sold by June 30. The company may pay a 3% commission on ATM sales.
- Commitments include up to $2.0 million in potential supply-agreement milestone payments. No material pending legal proceedings or material indemnification claims were reported.
Most important facts for investors to verify
- Whether the stated runway remains adequate as clinical spending, cash burn, and the effects of the July portfolio reprioritization develop.
- Clinical progress, safety, and efficacy for BDC-1001 and BDC-3042, and the timing and funding implications of related trials.
- Collaboration scope, performance, and deferred-revenue recognition, especially the Toray research-plan reevaluation and partner-funded work.
- Progress and testing of internal-control remediation, and whether the material weakness is ultimately resolved.
- Potential dilution if Bolt uses its shelf registration or ATM program to raise capital.